Author:
Hui Christina,Tsai Guochuan E.
Reference156 articles.
1. Mental Health: A Report of the Surgeon General. Adults and mental health: schizophrenia. [ONLINE] [cited 1 July 2009]; 269–285. Available from URL:
http://www.surgeongeneral.gov/library/mentalhealth/chapter4/sec4.html
2. American Psychiatric Association. Desk Reference to the Diagnostic Criteria from DSM-IV-TR. RR Donnelley & Sons, Washington, DC, 2000; pp. 153–155
3. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008; 33(9):2061–2079
4. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Ann Rev Pharmacol Toxicol 2002; 42:165–179
5. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007; 12(10):904–922
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Perspective Chapter - NMDA Treatments for CNS Disorders;Ketamine Revisited - New Insights into NMDA Inhibitors [Working Title];2021-10-28